Dianthus Therapeutics, Inc. (DNTH)
82.37
-0.06
(-0.07%)
USD |
NASDAQ |
Oct 09, 16:00
83.00
+0.63
(+0.76%)
After-Hours: 20:00
Dianthus Therapeutics EPS Diluted (Quarterly) : -0.8962 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.8962 |
| March 31, 2026 | -0.8501 |
| December 31, 2025 | -1.433 |
| September 30, 2025 | -0.9728 |
| June 30, 2025 | -0.8829 |
| March 31, 2025 | -0.8245 |
| December 31, 2024 | -0.8118 |
| September 30, 2024 | -0.7353 |
| June 30, 2024 | -0.5144 |
| March 31, 2024 | -0.5357 |
| December 31, 2023 | -0.7129 |
| September 30, 2023 | -3.779 |
| June 30, 2023 | -12.73 |
| March 31, 2023 | -129.67 |
| December 31, 2022 | -11.57 |
| September 30, 2022 | -142.45 |
| June 30, 2022 | -4.698 |
| March 31, 2022 | -6.245 |
| December 31, 2021 | -5.251 |
| Date | Value |
|---|---|
| September 30, 2021 | -4.760 |
| June 30, 2021 | -5.043 |
| March 31, 2021 | -5.762 |
| December 31, 2020 | -5.989 |
| September 30, 2020 | -5.861 |
| June 30, 2020 | -7.706 |
| March 31, 2020 | -8.134 |
| December 31, 2019 | -9.516 |
| September 30, 2019 | -8.650 |
| June 30, 2019 | -7.728 |
| March 31, 2019 | -7.101 |
| December 31, 2018 | -8.037 |
| September 30, 2018 | -7.765 |
| June 30, 2018 | -50.09 |
| March 31, 2018 | -5.049 |
| December 31, 2017 | -3.909 |
| September 30, 2017 | -3.130 |
| June 30, 2017 | -6.960 |
| March 31, 2017 | -2.336 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Verastem, Inc. | -0.3463 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -50.22M |
| Revenue (Quarterly) | 0.761M |
| Total Expenses (Quarterly) | 50.98M |
| Enterprise Value | 3.628B |
| Gross Profit Margin (Quarterly) | 85.94% |
| Profit Margin (Quarterly) | -6.60K% |
| Earnings Yield | -5.04% |
| Normalized Earnings Yield | -5.040 |